Kyowa Kirin Co. Ltd (KYKOF PINK) stock market data APIs
$15.6956
0(0%)
as of December 17, 2025
Try our APIs with
free plan!
Kyowa Kirin Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachromatic leukodystrophy; Orkedia for treatment of secondary hyperparathyroidism; and Romiplate to treat aplastic anemia. It also develops OTL-203 for the treatment of mucopolysaccharidosis type IH (hurler syndrome); KHK4083/AMG 451 to treat atopic dermatitis, prurigo nodularis, and asthma; OTL-201 for the treatment of mucopolysaccharidosis type IIIA (sanfilippo syndrome type A); ziftomenib for treating R/R acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951 for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123 to treat x-linked hypophosphatemia; KK2845 for the treatment of acute myeloid leukemia; KK4277 for treating systemic and cutaneous lupus erythematosus; Lumicef to treat palmoplantar pustulosis; KK2260 and KK2269 for the treatment of solid tumors; and KK8398 for the treatment of achondroplasia. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Prev. Close
15.6956
Open
15.6956
High
15.6956
Low
15.6956
52 wk Range
12.1508-17.13
Market Cap
8 295 M
P/E Ratio
33.7128
Shares Outstanding
523 M
Revenue
482 211 M
EPS
0.2109
Dividends (Yield)
0.0246
Beta
-0.006
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kyowa Kirin Co. Ltd data using free add-ons & libraries
Get Kyowa Kirin Co. Ltd Fundamental Data
Kyowa Kirin Co. Ltd Fundamental data includes:
- Net Revenue: 482 211 M
- EBITDA: 106 725 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 28.91
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kyowa Kirin Co. Ltd News
New
Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval
Kura Oncology Inc. (NASDAQ:KURA) is one of the stocks that will double in 2026. On November 24, Barclays analyst Etzer Darout raised the firm’s price target on Kura Oncology to $28 from $11 and main...
Kyowa Kirin (TSE:4151) Valuation Check as Shares Climb 11% Year to Date
Kyowa Kirin (TSE:4151) has been quietly grinding higher, with the stock up around 11% this year and roughly 7% over the past 3 months, hinting at improving sentiment around its drug pipeline. See our...
Kyowa Kirin announces management changes
* Kyowa Kirin (KYKOF [https://seekingalpha.com/symbol/KYKOF]) (KNBWY [https://seekingalpha.com/symbol/KNBWY]) appointed [https://seekingalpha.com/pr/20336175-kyowa-kirin-announces-proposed-appointme...
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
Leadership Changes to Take Effect Following Conclusion of Ordinary General Meeting of Shareholders in March 2026 Announcement Follows Year of Dual CEO / COO Model and Returns Company to Single Leader ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
